210 related articles for article (PubMed ID: 12688405)
41. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
Xu W; Song S; Huang Y; Gong Z
J Gastroenterol Hepatol; 2006 Aug; 21(8):1250-6. PubMed ID: 16872305
[TBL] [Abstract][Full Text] [Related]
42. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy.
Sukumaran V; Watanabe K; Veeraveedu PT; Thandavarayan RA; Gurusamy N; Ma M; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Hypertens Res; 2010 Jul; 33(7):695-702. PubMed ID: 20535115
[TBL] [Abstract][Full Text] [Related]
43. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
44. Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Xiang Y; Huang J
Acta Pharmacol Sin; 2000 Sep; 21(9):850-4. PubMed ID: 11501170
[TBL] [Abstract][Full Text] [Related]
45. Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity.
Goyal S; Bharti S; Sahoo KC; Sharma AK; Arya DS
Cardiovasc Toxicol; 2011 Jun; 11(2):148-56. PubMed ID: 21380857
[TBL] [Abstract][Full Text] [Related]
46. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
[TBL] [Abstract][Full Text] [Related]
47. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
48. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
Saisho Y; Komiya N; Hirose H
Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
[TBL] [Abstract][Full Text] [Related]
49. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
50. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
51. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy.
Yamamoto T; Sata M; Fukuda D; Takamoto S
Basic Res Cardiol; 2005 Jan; 100(1):84-91. PubMed ID: 15490202
[TBL] [Abstract][Full Text] [Related]
52. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
Oishi Y; Ozono R; Yoshizumi M; Akishita M; Horiuchi M; Oshima T
Life Sci; 2006 Dec; 80(1):82-8. PubMed ID: 17023005
[TBL] [Abstract][Full Text] [Related]
53. [Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
Xu R; Zhang Y; Zhang M; Li XC; Cai H; Chen WQ; Zhu H; Ge ZM; Zhang W
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3199-204. PubMed ID: 16405840
[TBL] [Abstract][Full Text] [Related]
54. Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Wang P; Tang F; Li R; Zhang H; Chen S; Liu P; Huang H
Pharmacol Res; 2007 May; 55(5):408-17. PubMed ID: 17324585
[TBL] [Abstract][Full Text] [Related]
55. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
Savoia C; Ebrahimian T; He Y; Gratton JP; Schiffrin EL; Touyz RM
J Hypertens; 2006 Dec; 24(12):2417-22. PubMed ID: 17082724
[TBL] [Abstract][Full Text] [Related]
57. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis.
Kashimura T; Hayashi M; Kodama M; Nakazawa M; Abe S; Yoshida T; Tachikawa H; Hanawa H; Kato K; Watanabe K; Aizawa Y
Jpn Heart J; 2003 Sep; 44(5):735-44. PubMed ID: 14587655
[TBL] [Abstract][Full Text] [Related]
58. [Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
Qu FZ; Liu ZH; Jiang B; Zou C; Li HX; Han LH; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):501-4. PubMed ID: 19927629
[TBL] [Abstract][Full Text] [Related]
59. New basic science initiatives with the angiotensin II receptor blocker valsartan.
de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S3-5. PubMed ID: 17199210
[TBL] [Abstract][Full Text] [Related]
60. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
